BIOM-02. IDENTIFYING MGMT ALTERATIONS AS BIOMARKERS OF SURVIVAL IN LUNG ADENOCARCINOMA WITH BRAIN METASTASES

EGFR-mutant lung adenocarcinomas (EGFRm-LUAD) have a higher risk of developing brain metastases (BM) compared to non-EGFR-mutant tumors. BM development has significant prognostic impact and leads to poorer patient survival. MGMT promoter methylation is known to determine response to therapy in other...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Mamatjan, Yasin, Zuccato, Jeffrey, Moraes, Fabio, Cabanero, Michael, Shali, Wumairehan, Weiss, Jessica, Tsao, Ming, Aldape, Kenneth, Shepherd, Frances, Zadeh, Gelareh
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Biomarkers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650414/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.002
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados